Buy fine quality research chemicals from Shanghai Chemical International Trade Co., Ltd

FUB-AMB

fub-ambFUB-AMB (which is also known as FUBINACA and MMB-FUBINACA) is a synthetic cannabinoid with a structure based on an indazole moiety. Like other synthetic cannabinoids that have come in to prevalence within the last decade it is a potent agonist at the CB1 cannabinoid receptor.

The structure of FUB-AMB contributes to its synthetic cannabinoid properties.  It is a structurally related to AB-FUBINACA, an earlier synthetic cannabanoid, the difference being that the terminal amide group of the valine has been replaced by a methyl ester to produce FUB-AMB. AB-FUBINACA had originally been developed by Pfizer whilst investigating synthetic cannabinoids for analgesic use. However it has not been pursued as a medicine for human usage.

FUB-AMB goes by the formal IUPAC name of methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate, has a relative molar mass of 383.4 grams and has an empirical molecular formula of C21H22FN3O3. It readily forms a solution in acetonitrile.

FUB-AMB is a full and potent agonist at the human cannabinoid receptor CB1. CB1 was first identified over 20 years ago as the primary point of action for the chemical delta-9 THC which is the principal psychoactive constituent in the herbal drug cannabis. In the last 15 years a plethora of synthetic cannabinoids have emerged from laboratories worldwide that have a higher affinity for the CB1 receptor than THC itself. THC is only a partial agonist at CB1 compared to the full agonist action of FUB-AMB at CB1.

See Also

This gives chemicals such as FUB AMB many similar properties to cannabis. However the drug profile of the synthetic cannabinoids is markedly different due to their high binding affinity and potency. This often results in stronger reported effects of synthetic cannabinoids than herbal cannabis but it also means people must exercise much more caution with respect to dosage with overdosage being a potential problem.

Effects of CB1 agonists include hypotension, euphoria, increased appetite, dissociative mind states, loss of motor control, reduction or increase in anxiety, sedation and possible psychedelic states.

Full physiological and toxicological profiling of this chemical has not been carried out.

This substance is novel and not for consumption by humans or animals.

Unverified online sources attest to the extremely high potency of this chemical. Reported dosages are sub 0.1 mg with doses being prepared by careful volumetric titration or use of mg sensitive scales. Reports are of a short duration of action. There is no apparent oral availability. The risk of overdosing on this chemical is present and extreme care should be taken. This chemical has been linked to adverse events such as agitation, paranoia and seizures.

Reports include a “stoning” effect, psychedelic visuals including open eyed and closed eyed visuals and mind expanding effects. In smaller doses it is said to have psychoactive properties roughly similar in quality to THC.

Online reports point to a typical mode of ingestion of dissolution in propylene glycol then administration by vaporisation.

It is reported to be approximately five times as potent as the synthetic cannabanoid JWH-18.